Joaquin Duato

Joaquín Duato (born April 1962) is a Spanish-American business executive serving as Chairman and Chief Executive Officer of Johnson & Johnson, the American multinational healthcare corporation. Appointed CEO in January 2022 and Chairman in January 2023, he is only the eighth chief executive in the company's nearly 140-year history.

A 35-year veteran of Johnson & Johnson, Duato rose through the ranks after joining the company's Spanish pharmaceutical division in 1989. He is credited with engineering the turnaround of Johnson & Johnson's struggling pharmaceutical business in the early 2000s and later oversaw the historic separation of the company's consumer health segment into Kenvue, an independent publicly traded company.

Early life and education

Duato was born in April 1962 and grew up in Valencia, Spain. His passion for healthcare was shaped by his family: his mother worked as a midwife, his grandfather was a pediatrician, and his grandmother was a pharmacist—all of whom practiced in his hometown.

As Duato has recalled: "I found my way in Johnson & Johnson in Spain, where I grew up. And also while growing up, I discovered my passion for health care. Health care is rooted in my family."

Duato pursued his higher education in business, earning a Master of Business Administration from ESADE Business School in Barcelona, one of Spain's most prestigious business institutions. He later obtained a Master of International Management from the Thunderbird School of Global Management in Phoenix, Arizona.

He speaks English, Spanish, and Italian fluently and holds dual citizenship in Spain and the United States.

Career at Johnson & Johnson

Early career (1989–2002)

Duato joined Johnson & Johnson in 1989, beginning his career with Janssen Pharmaceutica, the company's pharmaceutical division, in Spain. Over the following years, he held various leadership positions within the company, gaining comprehensive experience across different business sectors, geographies, and functions.

Rise to senior leadership (2002–2021)

After moving to the United States in 2002, Duato's career accelerated. In 2011, he was appointed Executive Vice President and Worldwide Chairman of the Pharmaceuticals division. In this role, he developed and implemented a growth strategy that transformed Johnson & Johnson's pharmaceutical business from a struggling operation into one of the company's strongest performers.

In 2018, Duato was promoted to Vice Chairman of Johnson & Johnson's Executive Committee. In this expanded role, he led both the pharmaceutical and consumer product divisions while also overseeing supply chain and technology operations. He served as interim Chief Information Officer during this period, demonstrating his versatility as an executive.

CEO and Chairman

On August 19, 2021, Johnson & Johnson announced that Duato would succeed Alex Gorsky as CEO, with the transition effective January 3, 2022. He was simultaneously appointed to the company's board of directors. In November 2022, he was elected Chairman of the Board, effective January 2023.

Under his leadership, Duato has overseen significant strategic changes, most notably the separation of Johnson & Johnson's consumer health segment into Kenvue, which became an independent publicly traded company. The move allowed Johnson & Johnson to focus on its pharmaceutical and medical devices businesses.

Personal life

Duato lives in Pennsylvania with his wife, whose name he has kept private. The couple has two grown children.

Despite his prominent position, Duato maintains significant privacy about his personal life, rarely discussing his family in public appearances. He has spoken more openly about the influence his family's healthcare background had on his career choice, describing how growing up surrounded by medical professionals instilled in him a belief in healthcare's power to improve lives.

Controversies

As CEO of Johnson & Johnson, Duato has navigated several significant legal and reputational challenges:

Talc litigation

Johnson & Johnson faces tens of thousands of lawsuits alleging that its baby powder and other talc products are linked to cancers, including ovarian cancer. In April 2025, a court rejected the company's request to approve a $9 billion settlement with claimants. The lawsuits allege that J&J and its subsidiaries knew about potential problems with their products but continued selling them.

When asked about leading through these challenges, Duato responded: "We do it with conviction. Conviction on the principles of our credo... When we make a mistake, we take responsibility. And when the facts, the science, and the law are on our side, we stand by our products."

Opioid crisis settlement

Johnson & Johnson was implicated in the broader opioid crisis that devastated American communities. The company agreed to pay $99 million to West Virginia alone to settle claims that it contributed to the epidemic. As part of a broader settlement with state attorneys general, J&J committed to pay $5 billion over nine years—part of a $26 billion agreement that also included the three largest U.S. drug distributors.

COVID-19 vaccine challenges

The company's COVID-19 vaccine program, which Duato helped oversee before becoming CEO, encountered multiple setbacks. U.S. authorities warned of the vaccine's increased risks of rare blood clots and Guillain-Barré syndrome, a rare immune disorder. These side effects limited the vaccine's market growth.

Additionally, millions of doses had to be discarded after the discovery of manufacturing problems at contract manufacturer Emergent BioSolutions. Johnson & Johnson eventually suspended sales guidance for its COVID vaccine amid declining demand and production issues.

Compensation

Duato is one of the highest-paid executives in the pharmaceutical industry:

• 2024: $24.3 million total compensation (14% decrease from 2023)
  • Base salary: $1.6 million
  • Bonus: $4 million
  • Equity awards: $15.7 million
  • Other compensation (including personal aircraft use and home security): $248,160

• 2023: $28.4 million (117% increase from 2022), making him the highest-paid CEO among major pharmaceutical companies

As of 2024, Duato directly owns approximately 0.017% of Johnson & Johnson's shares, valued at approximately $84 million.

Awards and honors

• Order of Civil Merit, Commander by Number (2023) – Bestowed by King Felipe VI of Spain for his contributions to Spanish-American relations and healthcare leadership
• ESADE Award (2022) – Recognition from his business school alma mater for leadership excellence
• NJBIZ Manufacturing Power 50 (2021) – Ranked #3
• Healthcare Businesswomen's Association Honorable Mentor (2017)

Board memberships

• Hess Corporation – Board of Directors
• UNICEF USA – Board member
• Tsinghua University School of Pharmaceutical Sciences – Board member
• United States-Spain Council – Former board member
• Pharmaceutical Research and Manufacturers of America (PhRMA) – Chair (2017–2018)
• Council for Inclusive Capitalism – Member